JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


The Journal of Nuclear Medicine Vol. 40 No. 4 625-630
© 1999 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mozley, P. D.
Right arrow Articles by Alavi, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mozley, P. D.
Right arrow Articles by Alavi, A.

Radiation Dosimetry of a 99mTc-Labeled IgM Murine Antibody to CD15 Antigens on Human Granulocytes

P. David Mozley, James B. Stubbs, Stefan H. Dresel, Eleathea D. Barraclough, Terry Smith, Mohan Patel, Cynthia Finkelman, Richard B. Sparks, Mathew L. Thakur, Ajit Mathur and Abass Alavi

University of Pennsylvania, Philadelphia
Thomas Jefferson University, Philadelphia, Pennsylvania
Internal Dosimetry Systems of Oak Ridge, Oak Ridge, Tennessee
Palatin Technologies, Inc., Princeton, New Jersey

Correspondence: For correspondence or reprints contact: P. David Mozley, MD, 110-D Donner Building, HUP, 3400 Spruce St., Philadelphia, PA 19104.

ABSTRACT

99mTc-labeled anti-stage specific embryonic antigen-1 (anti-SSEA-1) is an injectable IgM antibody derived from mice. It binds to CD15 antigens on some granulocytic subpopulations of human white blood cells in vivo after systemic administration. The purpose of this study was to measure biodistribution of 99mTc-labeled anti-SSEA-1 and perform radiation dosimetry in 10 healthy human volunteers. Methods: Transmission scans and whole-body images were acquired sequentially on a dual-head camera for 32 h after the intravenous administration of about 370 MBq (10.0 mCi) of the radiopharmaceutical. Renal excretion fractions were measured from 10 to 14 discrete urine specimens voided over 27.9 ± 2.0 h. Multiexponential functions were fit iteratively to the time-activity curves for 17 regions of interest using a nonlinear least squares regression algorithm. The curves were integrated numerically to yield source organ residence times. Gender-specific radiation doses were then estimated individually for each subject, using the MIRD technique, before any results were averaged. Results: Quantification showed that the kidneys excreted 39.5% ± 6.5% of the administered dose during the first 24 h after administration. Image analysis showed that 10%–14% of the radioactivity went to the spleen, while more than 40% went to the liver. Residence times were longest in the liver (3.37 h), followed by the bone marrow (1.09 h), kidneys (0.84 h) and the spleen (0.65 h). The dose-limiting organ in both men and women was the spleen, which received an average of 0.062 mGy/MBq (0.23 rad/mCi, range 0.08–0.30 rad/mCi), followed by the kidneys (0.051 mGy/MBq), liver (0.048 mGy/MBq) and urinary bladder (0.032 mGy/MBq). The effective dose equivalent was 0.018 mSv/MBq (0.068 rem/mCi). Conclusion: The findings suggest that the radiation dosimetry profile for this new infection imaging agent is highly favorable.

Key Words: 99mTc • anti-stage specific embryonic antigen-1 antibody • infection • radionuclide




This article has been cited by other articles:


Home page
J. Nucl. Med. Technol.Home page
C. Love and C. J. Palestro
Radionuclide Imaging of Infection
J. Nucl. Med. Technol., June 1, 2004; 32(2): 47 - 57.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1999 by the Society of Nuclear Medicine.